Aarey Financial Statements From 2010 to 2025

Stocks . India . 
Stock . Aarey Drugs Pharmaceuticals
AAREYDRUGS   38.22  1.77  4.86%   
Aarey Drugs financial statements provide useful quarterly and yearly information to potential Aarey Drugs Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aarey Drugs financial statements helps investors assess Aarey Drugs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aarey Drugs' valuation are summarized below:
Gross Profit
172.2 M
Profit Margin
0.0099
Market Capitalization
1.1 B
Enterprise Value Revenue
0.2521
Revenue
5.8 B
There are over eighty available fundamental signals for Aarey Drugs Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Aarey Drugs' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction.

Aarey Drugs Total Revenue

2.7 Billion

Check Aarey Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aarey Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 20.5 M, Selling General Administrative of 3.5 M or Selling And Marketing Expenses of 1.9 M, as well as many indicators such as . Aarey financial statements analysis is a perfect complement when working with Aarey Drugs Valuation or Volatility modules.
  
This module can also supplement various Aarey Drugs Technical models . Check out the analysis of Aarey Drugs Correlation against competitors.

Aarey Drugs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding18.9 M29.2 M20.1 M
Slightly volatile
Total Assets3.7 B3.5 B1.9 B
Slightly volatile
Short and Long Term Debt Total378.6 M360.6 M165.6 M
Slightly volatile
Other Current Liabilities110.9 M105.6 M49 M
Slightly volatile
Total Current Liabilities2 B1.9 B1.1 B
Slightly volatile
Total Stockholder Equity1.6 B1.5 B791.6 M
Slightly volatile
Property Plant And Equipment Net100.9 M149.1 M100.6 M
Slightly volatile
Net Debt359.3 M342.2 M156.8 M
Slightly volatile
Retained Earnings641.3 M610.7 M274.2 M
Slightly volatile
Cash19.3 M18.3 M8.7 M
Slightly volatile
Non Current Assets Total250 M238.1 M131.7 M
Slightly volatile
Cash And Short Term Investments34.9 M33.2 M13.5 M
Slightly volatile
Liabilities And Stockholders Equity3.7 B3.5 B1.9 B
Slightly volatile
Non Current Liabilities Total48 M45.7 M17.8 M
Slightly volatile
Inventory869.3 M827.9 M244.3 M
Slightly volatile
Other Current Assets137.5 M209 M175.3 M
Pretty Stable
Other Stockholder Equity623.2 M593.5 M292.6 M
Slightly volatile
Total Liabilities2.1 B2 B1.1 B
Slightly volatile
Total Current Assets3.4 B3.2 B1.7 B
Slightly volatile
Common Stock197.1 M322.6 M205.4 M
Slightly volatile
Accounts Payable835.9 M1.5 B809.8 M
Slightly volatile
Net Receivables1.1 B2.1 B1.1 B
Slightly volatile
Current Deferred Revenue14.5 M15.2 M27.8 M
Slightly volatile
Short Term Investments12.7 M14.9 M10 M
Slightly volatile
Accumulated Other Comprehensive Income18 M28.3 M15.4 M
Slightly volatile
Other Liabilities19.9 M16.7 M15.4 M
Slightly volatile
Net Tangible Assets1 B1.3 B934.4 M
Slightly volatile
Net Invested Capital1.4 B1.9 B1.1 B
Slightly volatile
Short and Long Term Debt205.6 M323.5 M128.7 M
Slightly volatile
Net Working Capital952.5 M1.3 B822.9 M
Slightly volatile
Property Plant Equipment143.8 M166.4 M131.1 M
Slightly volatile
Capital Stock273.1 M322.6 M247.3 M
Slightly volatile
Property Plant And Equipment Gross343.6 M389.6 M295.8 M
Slightly volatile

Aarey Drugs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization20.5 M19.5 M10.8 M
Slightly volatile
Selling General Administrative3.5 M3.7 M3.5 M
Slightly volatile
Selling And Marketing Expenses1.9 M2 M4 M
Pretty Stable
Total Revenue2.7 B4.5 B3 B
Slightly volatile
Gross Profit81.3 M157.3 M89.5 M
Slightly volatile
Other Operating Expenses2.7 B4.5 B2.9 B
Slightly volatile
Operating Income3.1 M3.3 M39.5 M
Pretty Stable
EBIT117.3 M111.8 M59.5 M
Slightly volatile
EBITDA137.9 M131.3 M70.3 M
Slightly volatile
Cost Of Revenue2.6 B4.4 B2.9 B
Slightly volatile
Total Operating Expenses159.4 M151.8 M68.5 M
Slightly volatile
Income Before Tax46.5 M61.4 M49.7 M
Slightly volatile
Net Income34.5 M53.9 M37.2 M
Slightly volatile
Income Tax Expense12 M7.6 M12.4 M
Slightly volatile
Interest Expense52 M49.6 M21.2 M
Slightly volatile
Tax Provision5.6 M5.9 M18.3 M
Slightly volatile
Interest Income30.3 M56 M28.7 M
Slightly volatile
Net Income From Continuing Ops45.8 M42.2 M57.5 M
Slightly volatile
Reconciled Depreciation13.8 M19.5 M10.7 M
Slightly volatile
Net Income Applicable To Common Shares69.5 M75.3 M64 M
Slightly volatile

Aarey Drugs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow8.4 M8.1 M8.3 M
Very volatile
Depreciation9.9 M19.5 M10.2 M
Slightly volatile
Capital Expenditures16.4 M8.3 M14.8 M
Pretty Stable
Net Income47.9 M53.9 M48.7 M
Slightly volatile
End Period Cash Flow9.4 M18.3 M9.9 M
Pretty Stable
Change To Netincome21.8 M21.8 M17.1 M
Slightly volatile

Aarey Fundamental Market Drivers

Cash And Short Term Investments28.9 M

About Aarey Drugs Financial Statements

Aarey Drugs shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aarey Drugs investors may analyze each financial statement separately, they are all interrelated. The changes in Aarey Drugs' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aarey Drugs' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue15.2 M14.5 M
Total Revenue4.5 B2.7 B
Cost Of Revenue4.4 B2.6 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ZLABZai Lab
ASLEAerSale Corp
ATSAT S Austria

Additional Tools for Aarey Stock Analysis

When running Aarey Drugs' price analysis, check to measure Aarey Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarey Drugs is operating at the current time. Most of Aarey Drugs' value examination focuses on studying past and present price action to predict the probability of Aarey Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarey Drugs' price. Additionally, you may evaluate how the addition of Aarey Drugs to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY